Bionomics is a clinical stage biopharmaceutical company. Co utilizes its proprietary platform technologies to discover and develop a pipeline, drug candidates focused on the treatment of central nervous system disorders and on the treatment of cancer. Co.'s key drug candidate BNC210, which for the treatment of generalized anxiety disorder, is a proprietary negative allosteric modulator of the alpha-7 nicotinic acetylcholine receptor. Co. also develops BNC101, which its lead humanized monoclonal antibody targeting a key receptor on cancer stem cells that is overexpressed in metastatic colorectal cancer, metastatic pancreatic cancer and many other solid tumors.
Research suggests that directors know their companies better than the market. For many investors it is intuitive that following the trading patterns of directors and other company insiders can lead to successful investing. They often have detailed knowledge about their companies and generally know when the shares are incorrectly valued. However, that is not always true and with large numbers of trades reported every day on exchanges around the world, it is difficult to know which to follow.
SmartInsider provides valuable insight by supplementing and analysing reported transactions to achieve real insight with a focus on identifying the ‘Smart Insiders’ and highlighting the stand-out transactions they make. Our proven track-record and thirty year pedigree are backed by more recent statistical analysis of historical data.
Our service offers director dealing reports, company reports and monthly summaries with a fully interactive website for further research. We can also provide quant feeds and customised alerts to suit every need at the frequency preferred. SmartInsider covers all markets with a regulatory requirement to report insider activity, over 60,000 companies across 55 markets.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.